Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabinoid topical solution is a water-soluble gel formulation developed by BOL Pharma containing cannabinoids, specifically delta-9-tetrahydrocannabinol (THC) and/or cannabidiol (CBD). The product is designed for topical administration to treat inflammatory and painful conditions of the skin and nerves, including atopic dermatitis, psoriasis, acne, and neuropathic pain. By delivering cannabinoids directly to the affected area, the solution aims to modulate the local endocannabinoid system to reduce inflammation and provide analgesic relief while minimizing systemic exposure. The development program includes both preclinical studies and ongoing clinical trials for various dermatological and neurological indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabinoid topical solution.